Table 2.
Progression-free and overall survival for breast cancer patients treated with NACa
| Progression-free survival (PFS) | |||||
|---|---|---|---|---|---|
| Time-to-event endpoint | N | Events | Point estimate | 80% Confidence interval | |
| Lower limit | Upper limit | ||||
| Median | 16 | 10 | 5.7 years | 0.4 years | 13.4 years |
| 1-year rate | 71% | 48% | 85% | ||
| 3-year rate | 64% | 40% | 80% | ||
| 5-year rate | 52% | 30% | 70% | ||
| 10-year rate | 42% | 20% | 62% | ||
| Overall survival (OS) | |||||
| Median | 16 | 10 | 6.3 years | 0.8 years | N/A |
| 1-year rate | 81% | 58% | 92% | ||
| 3-year rate | 66% | 43% | 82% | ||
| 5-year rate | 60% | 37% | 76% | ||
| 10-year rate | 40% | 20% | 60% | ||
N/A not applicable
a
NAC neoadjuvant chemotherapy, Events death for overall; death or progression for progression-free survival